113 related articles for article (PubMed ID: 36400662)
1. Real world impact of 13vPCV in preventing invasive pneumococcal pneumonia in Australian children: A national study.
Homaira N; Strachan R; Quinn H; Beggs S; Bhuiyan M; Bowen A; Fawcett LK; Gilbert GL; Lambert SB; Macartney K; Marshall HS; Martin Md AC; McCallum G; McCullagh A; McDonald T; Selvadurai H; McIntyre P; Oftadeh S; Ranganathan PhD S; Saunders T; Suresh S; Wainwright C; Wilson A; Wong M; Jaffe A; Snelling T
Vaccine; 2023 Jan; 41(1):85-91. PubMed ID: 36400662
[TBL] [Abstract][Full Text] [Related]
2. Assessing the impact of the 13 valent pneumococcal vaccine on childhood empyema in Australia.
Strachan R; Homaira N; Beggs S; Bhuiyan MU; Gilbert GL; Lambert SB; Macartney K; Marshall H; Martin AC; McCallum GB; McCullagh A; McDonald T; McIntyre P; Oftadeh S; Ranganathan S; Suresh S; Wainwright CE; Wilson A; Wong M; Snelling T; Jaffé A
Thorax; 2021 May; 76(5):487-493. PubMed ID: 33504566
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of impact of 23 valent pneumococcal polysaccharide vaccine following 7 valent pneumococcal conjugate vaccine in Australian Indigenous children.
Jayasinghe S; Chiu C; Menzies R; Lehmann D; Cook H; Giele C; Krause V; McIntyre P
Vaccine; 2015 Nov; 33(48):6666-74. PubMed ID: 26519550
[TBL] [Abstract][Full Text] [Related]
4. Pneumococcal bacteraemia in adults over a 10-year period (2011-2020): a clinical and serotype analysis.
Colaco CMG; O'Sullivan M; Zhang H; Huynh D; Sintchenko V; Oftadeh S; Gilbert GL; Dotel R
Intern Med J; 2023 Nov; 53(11):2028-2034. PubMed ID: 36872866
[TBL] [Abstract][Full Text] [Related]
5. Invasive pneumococcal pneumonia caused by 13-valent pneumococcal conjugate vaccine types in children with different schedules.
Lee HY; Hsieh YC; Liu CC; Huang YC; Chang KY; Chi H; Chang LY; Huang YC; Huang LM;
J Microbiol Immunol Infect; 2018 Apr; 51(2):199-206. PubMed ID: 29021105
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.
Cohen C; von Mollendorf C; de Gouveia L; Lengana S; Meiring S; Quan V; Nguweneza A; Moore DP; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Finlayson H; Varughese S; O'Brien KL; Zell ER; Klugman KP; Whitney CG; von Gottberg A;
Lancet Glob Health; 2017 Mar; 5(3):e359-e369. PubMed ID: 28139443
[TBL] [Abstract][Full Text] [Related]
7. High Prevalence of Vaccine-Type Infections Among Children with Pneumococcal Pneumonia and Effusion After 13-Valent Pneumococcal Conjugate Vaccine Introduction in the Dominican Republic.
Ahmed SS; Lessa FC; Coradin H; Sánchez J; Carvalho MDG; Soda E; Peña C; Fernández J; Cedano D; Whitney CG; Feris-Iglesias J
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S228-S236. PubMed ID: 34469563
[TBL] [Abstract][Full Text] [Related]
8. Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010-2015.
Silva-Costa C; Brito MJ; Pinho MD; Friães A; Aguiar SI; Ramirez M; Melo-Cristino J; ;
Emerg Infect Dis; 2018 Jul; 24(7):1307-1314. PubMed ID: 29912700
[TBL] [Abstract][Full Text] [Related]
9. Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany.
Goettler D; Streng A; Kemmling D; Schoen C; von Kries R; Rose MA; van der Linden M; Liese JG
Vaccine; 2020 Jan; 38(3):570-577. PubMed ID: 31735502
[TBL] [Abstract][Full Text] [Related]
10. Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study.
Kabir A; Randall D; Newall AT; Moore HC; Jayasinghe S; Fathima P; Liu B; McIntyre P; Gidding HF
Vaccine; 2023 Aug; 41(37):5454-5460. PubMed ID: 37507273
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in HIV-infected and -uninfected children in south africa: a matched case-control study.
Cohen C; von Mollendorf C; de Gouveia L; Naidoo N; Meiring S; Quan V; Nokeri V; Fortuin-de Smit M; Malope-Kgokong B; Moore D; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Kularatne R; Conklin L; O'Brien KL; Zell ER; Klugman K; Whitney CG; von Gottberg A;
Clin Infect Dis; 2014 Sep; 59(6):808-18. PubMed ID: 24917657
[TBL] [Abstract][Full Text] [Related]
12. Direct effectiveness of pneumococcal polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.
Kim JH; Chun BC; Song JY; Kim HY; Bae IG; Kim DM; Choi YH; Jun YH; Choi WS; Kang SH; Kwon HH; Jeong HW; Kee SY; Hur J; Chung JW; Yoon YK; Sohn JW; Yang KS; Kim MJ
Vaccine; 2019 May; 37(21):2797-2804. PubMed ID: 31005428
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
[TBL] [Abstract][Full Text] [Related]
14. High nasopharyngeal carriage of non-vaccine serotypes in Western Australian aboriginal people following 10 years of pneumococcal conjugate vaccination.
Collins DA; Hoskins A; Bowman J; Jones J; Stemberger NA; Richmond PC; Leach AJ; Lehmann D
PLoS One; 2013; 8(12):e82280. PubMed ID: 24349245
[TBL] [Abstract][Full Text] [Related]
15. Pneumococcal disease in South Australia: vaccine success but no time for complacency.
Johnson DR; D'Onise K; Holland RA; Raupach JC; Koehler AP
Vaccine; 2012 Mar; 30(12):2206-11. PubMed ID: 22273663
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study.
Domingues CM; Verani JR; Montenegro Renoiner EI; de Cunto Brandileone MC; Flannery B; de Oliveira LH; Santos JB; de Moraes JC;
Lancet Respir Med; 2014 Jun; 2(6):464-71. PubMed ID: 24726406
[TBL] [Abstract][Full Text] [Related]
17. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
18. [Bacteremic pneumococcal pneumonia].
Pineda Solas V; Pérez Benito A; Domingo Puiggros M; Larramona Carrera H; Segura Porta F; Fontanals Aymerich D
An Esp Pediatr; 2002 Nov; 57(5):408-13. PubMed ID: 12467543
[TBL] [Abstract][Full Text] [Related]
19. Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study.
Shrestha S; Gurung M; Amatya P; Bijukchhe S; Bose AS; Carter MJ; Gautam MC; Gurung S; Hinds J; Kandasamy R; Kelly S; Khadka B; Maskey P; Mujadidi YF; O'Reilly PJ; Pokhrel B; Pradhan R; Shah GP; Shrestha S; Wahl B; O'Brien KL; Knoll MD; Murdoch DR; Kelly DF; Thorson S; Voysey M; Pollard AJ;
Lancet Glob Health; 2022 Oct; 10(10):e1494-e1504. PubMed ID: 36113533
[TBL] [Abstract][Full Text] [Related]
20. Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in Blantyre, Malawi, 2006-18: prospective observational time-series and case-control studies.
Bar-Zeev N; Swarthout TD; Everett DB; Alaerts M; Msefula J; Brown C; Bilima S; Mallewa J; King C; von Gottberg A; Verani JR; Whitney CG; Mwansambo C; Gordon SB; Cunliffe NA; French N; Heyderman RS;
Lancet Glob Health; 2021 Jul; 9(7):e989-e998. PubMed ID: 34143997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
